跳至主要内容
临床试验/NCT05642793
NCT05642793招募中2 期

Effect of Postvitrectomy Proactive Use of Conbercept on Postoperative Complications in PDR Patients

Peking University Third Hospital1 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2022年4月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
招募中
入组人数
80
试验地点
1
主要终点
rate of postvitrectomy complication

研究概览

简要总结

This is an unmasking randomized clinical trial. the main purpose of this study is to analyze whether posvitrectomy proactive use of conbercept can reduce the rate of postoperative complication in PDR patients.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
19 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • PDR patients undergoing vitrectomy

排除标准

  • patients who had received intravitreal injection or systemic use of all types of anti-VEGF agents in the recent three months before vitrectomy
  • patients who had received intravitreal injection or systemic use of all types of steroid in the recent one month before vitrectomy
  • patients who had received complete PRP before vitrectomy
  • patients who are pregnant

研究组 & 干预措施

group 1 (proactive use of conbercept after vitrectomy)

Experimental

proactive use of conbercept after vitrectomy

干预措施: proactive Anti-VEGF (conbercept) use (Drug)

group 2 (passive use of conbercept after vitrectomy)

Experimental

passive use of conbercept after vitrectomy

干预措施: passive Anti-VEGF (conbercept) use (Drug)

结局指标

主要结局

rate of postvitrectomy complication

时间窗: 6 months

postvitrectomy DME, VH (recurrent or nonabsorbent), NVG

次要结局

  • postvitrectomy BCVA(6 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Chen Huijin

Clinical Professor

Peking University Third Hospital

研究点 (1)

Loading locations...

相似试验